gonarthrosis; therapy; Karmolis gel.

Objective: to evaluate the efficacy, tolerance, and safety of Carmolis topical gel in patients with gonarthrosis. Subjects and methods. The investigation enrolled 60 patients with knee osteoarthrosis (OA) who were divided into two groups: 1) 40 patients received Carmolis topical gel in addition to n...

Full description

Saved in:
Bibliographic Details
Main Authors: B. V. Zavodovsky, E. E. Mozgovaya, Yu. R. Akhverdyan, I. A. Zborovskaya
Format: Article
Language:Russian
Published: IMA PRESS LLC 2014-06-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/1950
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849773868066013184
author B. V. Zavodovsky
E. E. Mozgovaya
Yu. R. Akhverdyan
I. A. Zborovskaya
author_facet B. V. Zavodovsky
E. E. Mozgovaya
Yu. R. Akhverdyan
I. A. Zborovskaya
author_sort B. V. Zavodovsky
collection DOAJ
description Objective: to evaluate the efficacy, tolerance, and safety of Carmolis topical gel in patients with gonarthrosis. Subjects and methods. The investigation enrolled 60 patients with knee osteoarthrosis (OA) who were divided into two groups: 1) 40 patients received Carmolis topical gel in addition to nonsteroidal anti-inflammatory drugs (NSAIDs); 2) 20 patients took NSAIDS only (a control group). The treatment duration was 2 weeks. In both groups, therapeutic effectiveness was evaluated from changes in the WOMAC index, pain intensity at rest and during movement by the visual analog scale (VAS). The disease activity was also assessed by a physician and a patient (a Likert scale), local swelling and hyperthermia of the affected joint, the efficiency of treatment, and daily needs for NSAIDs were deter- mined. Results. The performed treatment in both patent groups showed positive clinical changes. Combination therapy involving Carmolis gel displayed greater reductions in WOMAC pain and resting and movement pain than in the con- trol group (as assessed by VAS). On completion of the investigation, considerable improvement was, in the physicians' opinion, noted in 38 (95%) patients using Carmolis, which coincided with self-evaluations of the patients. During Carmolis application, the starting dose of NSAIDs could be reduced in 18 (45%) patients. Adverse reactions occurred infrequently and required no therapy discontinuation. Conclusion. Carmolis topical gel is effective in relieving clinical symptoms in patients with gonarthrosis, well tolerated, and safe, which can recommend its use in the combination treatment of knee OA.
format Article
id doaj-art-d3651a4201c6462dad1622dad986c65f
institution DOAJ
issn 1995-4484
1995-4492
language Russian
publishDate 2014-06-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj-art-d3651a4201c6462dad1622dad986c65f2025-08-20T03:01:55ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922014-06-0152334234610.14412/1995-4484-2014-342-3461884gonarthrosis; therapy; Karmolis gel.B. V. Zavodovsky0E. E. Mozgovaya1Yu. R. Akhverdyan2I. A. Zborovskaya3Research Institute of Clinical and Experimental Rheumatology, Russian Academy of Medical Sciences, Volgograd, RussiaResearch Institute of Clinical and Experimental Rheumatology, Russian Academy of Medical Sciences, Volgograd, RussiaResearch Institute of Clinical and Experimental Rheumatology, Russian Academy of Medical Sciences, Volgograd, RussiaResearch Institute of Clinical and Experimental Rheumatology, Russian Academy of Medical Sciences, Volgograd, RussiaObjective: to evaluate the efficacy, tolerance, and safety of Carmolis topical gel in patients with gonarthrosis. Subjects and methods. The investigation enrolled 60 patients with knee osteoarthrosis (OA) who were divided into two groups: 1) 40 patients received Carmolis topical gel in addition to nonsteroidal anti-inflammatory drugs (NSAIDs); 2) 20 patients took NSAIDS only (a control group). The treatment duration was 2 weeks. In both groups, therapeutic effectiveness was evaluated from changes in the WOMAC index, pain intensity at rest and during movement by the visual analog scale (VAS). The disease activity was also assessed by a physician and a patient (a Likert scale), local swelling and hyperthermia of the affected joint, the efficiency of treatment, and daily needs for NSAIDs were deter- mined. Results. The performed treatment in both patent groups showed positive clinical changes. Combination therapy involving Carmolis gel displayed greater reductions in WOMAC pain and resting and movement pain than in the con- trol group (as assessed by VAS). On completion of the investigation, considerable improvement was, in the physicians' opinion, noted in 38 (95%) patients using Carmolis, which coincided with self-evaluations of the patients. During Carmolis application, the starting dose of NSAIDs could be reduced in 18 (45%) patients. Adverse reactions occurred infrequently and required no therapy discontinuation. Conclusion. Carmolis topical gel is effective in relieving clinical symptoms in patients with gonarthrosis, well tolerated, and safe, which can recommend its use in the combination treatment of knee OA.https://rsp.mediar-press.net/rsp/article/view/1950gonarthrosistherapykarmolis gel.
spellingShingle B. V. Zavodovsky
E. E. Mozgovaya
Yu. R. Akhverdyan
I. A. Zborovskaya
gonarthrosis; therapy; Karmolis gel.
Научно-практическая ревматология
gonarthrosis
therapy
karmolis gel.
title gonarthrosis; therapy; Karmolis gel.
title_full gonarthrosis; therapy; Karmolis gel.
title_fullStr gonarthrosis; therapy; Karmolis gel.
title_full_unstemmed gonarthrosis; therapy; Karmolis gel.
title_short gonarthrosis; therapy; Karmolis gel.
title_sort gonarthrosis therapy karmolis gel
topic gonarthrosis
therapy
karmolis gel.
url https://rsp.mediar-press.net/rsp/article/view/1950
work_keys_str_mv AT bvzavodovsky gonarthrosistherapykarmolisgel
AT eemozgovaya gonarthrosistherapykarmolisgel
AT yurakhverdyan gonarthrosistherapykarmolisgel
AT iazborovskaya gonarthrosistherapykarmolisgel